A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in healthy adult subjects.

Trial Profile

A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in healthy adult subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload; Myelodysplastic syndromes
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 18 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top